Perspective from Gautam Mankaney, MD
Source/Disclosures
Disclosures: The authors report no relevant financial disclosures.
August 05, 2020
1 min read
Save

FMT safe, shows promise in alcohol use disorder

Perspective from Gautam Mankaney, MD
Source/Disclosures
Disclosures: The authors report no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Fecal microbiota transplantation was associated with short-term reductions in alcohol craving and consumption in men with alcohol use disorder, according to research published in Hepatology.

Jasmohan S. Bajaj, MD, of the division of gastroenterology, hepatology and nutrition at Virginia Commonwealth University, and colleagues wrote that therapies that can encourage reduced alcohol use are critical tools against mortality and morbidities caused by alcohol use disorder (AUD) and alcohol-related cirrhosis.

“Other studies have demonstrated a potential role of microbiota in the addictive behavior,” they wrote. “We have shown that in patients with advanced cirrhosis who are not currently drinking, the altered gut-brain axis responds to fecal microbiota transplant.”

Researchers randomly assigned men with AUD-related cirrhosis with problem drinking (AUD identification test [IT]-10>8) to receive one placebo (n = 10) or FMT enema (n = 10) from a donor enriched in Lachnospiraceae and Ruminococcacea. The primary outcome of the study was safety at 6 months.

Investigators assessed alcohol craving, alcohol consumption, quality of life, cognition, serum IL-6, lipopolysaccharide-binding protein, plasma/stool short-chain fatty acids and stool microbiota at baseline and after 15 days.

Bajaj and colleagues found that a greater proportion of patients in the FMT group experienced significant reductions in alcohol cravings compared with the placebo group (90% vs. 30%; P = .02). They also had lower urinary ethylglucuronide/creatinine, improved cognition and psychosocial QOL.

Microbial diversity increased among the FMT group, with higher Ruminococcaceae and other short chain fatty acid producing taxa.

After 6 months, the placebo group had more patients with any severe adverse event (8 vs. 2; P = .02) and AUD-related severe adverse events (7 vs. 1; P = .02).

“We conclude in this phase 1 trial that FMT in men with cirrhosis is safe, associated with reduction in short-term craving and consumption with beneficial microbial change,” Bajaj and colleagues wrote. “The FMT assigned group also demonstrated lower AUD-related events over the follow-up, which need to be confirmed and extended in larger number of patients with AUD.”